OA19128A - Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes. - Google Patents
Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes. Download PDFInfo
- Publication number
- OA19128A OA19128A OA1201800512 OA19128A OA 19128 A OA19128 A OA 19128A OA 1201800512 OA1201800512 OA 1201800512 OA 19128 A OA19128 A OA 19128A
- Authority
- OA
- OAPI
- Prior art keywords
- formulation
- composition
- cells
- cell
- patient
- Prior art date
Links
- 206010012601 Diabetes mellitus Diseases 0.000 title abstract description 7
- 230000002503 metabolic Effects 0.000 title description 4
- 230000001684 chronic Effects 0.000 title description 2
- 239000002417 nutraceutical Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 124
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 19
- 239000008103 glucose Substances 0.000 claims abstract description 19
- 210000000056 organs Anatomy 0.000 claims abstract description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940116269 Uric Acid Drugs 0.000 claims abstract description 6
- 210000000577 Adipose Tissue Anatomy 0.000 claims abstract description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Resveratrol Natural products C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 58
- 229940016667 resveratrol Drugs 0.000 claims description 29
- 235000021283 resveratrol Nutrition 0.000 claims description 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 23
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 21
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 20
- 235000018417 cysteine Nutrition 0.000 claims description 17
- 210000004369 Blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 239000004475 Arginine Substances 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 11
- 210000001367 Arteries Anatomy 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 94
- 229960001031 Glucose Drugs 0.000 abstract description 18
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000008589 Obesity Diseases 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 7
- 235000020824 obesity Nutrition 0.000 abstract description 7
- 230000036740 Metabolism Effects 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 230000035786 metabolism Effects 0.000 abstract description 5
- 230000000271 cardiovascular Effects 0.000 abstract description 3
- 230000001120 cytoprotect Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 206010058108 Dyslipidaemia Diseases 0.000 abstract description 2
- 206010061227 Lipid metabolism disease Diseases 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 102100017238 AVP Human genes 0.000 abstract 1
- 101700084127 AVP Proteins 0.000 abstract 1
- 206010003119 Arrhythmia Diseases 0.000 abstract 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 abstract 1
- 229940107161 Cholesterol Drugs 0.000 abstract 1
- 241000448280 Elates Species 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010022489 Insulin resistance Diseases 0.000 abstract 1
- 208000010125 Myocardial Infarction Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010064 diabetes insipidus Diseases 0.000 abstract 1
- 201000005569 gout Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000000268 renotropic Effects 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 210000004027 cells Anatomy 0.000 description 72
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 64
- 230000000694 effects Effects 0.000 description 38
- 108090001061 Insulin Proteins 0.000 description 32
- 102000004877 Insulin Human genes 0.000 description 32
- 229960002433 Cysteine Drugs 0.000 description 18
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 14
- 210000004698 Lymphocytes Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 238000004166 bioassay Methods 0.000 description 12
- 241001672739 Artemia salina Species 0.000 description 11
- 210000003734 Kidney Anatomy 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 229960002449 Glycine Drugs 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- 229960003121 arginine Drugs 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- 239000001963 growth media Substances 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 230000004083 survival Effects 0.000 description 8
- 230000004075 alteration Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002588 toxic Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 210000001736 Capillaries Anatomy 0.000 description 6
- 210000004185 Liver Anatomy 0.000 description 6
- 210000001616 Monocytes Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000001738 genotoxic Effects 0.000 description 6
- 239000002609 media Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- 241000283953 Lagomorpha Species 0.000 description 5
- 239000007759 RPMI Media 1640 Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissues Anatomy 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N Alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 229960003180 Glutathione Drugs 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- VLEUZFDZJKSGMX-ONEGZZNKSA-N Pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 210000003501 Vero Cells Anatomy 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001472 cytotoxic Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000002354 daily Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 231100000025 genetic toxicology Toxicity 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229940020899 hematological Enzymes Drugs 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229960001322 trypsin Drugs 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 210000000988 Bone and Bones Anatomy 0.000 description 3
- 102100011502 GPER1 Human genes 0.000 description 3
- 101700032714 GPER1 Proteins 0.000 description 3
- COCFEDIXXNGUNL-RFKWWTKHSA-N Glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108010057186 Insulin Glargine Proteins 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N N'-amino-N-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 101710026488 SOD2 Proteins 0.000 description 3
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000002939 deleterious Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000003834 intracellular Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 230000002438 mitochondrial Effects 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 206010059512 Apoptosis Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 210000000601 Blood Cells Anatomy 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 101700036312 CONA Proteins 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 206010061428 Decreased appetite Diseases 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 210000003584 Mesangial Cells Anatomy 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102100000077 PPARG Human genes 0.000 description 2
- 101700070851 PPARG Proteins 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 206010036067 Polydipsia Diseases 0.000 description 2
- 102100007214 SIRT1 Human genes 0.000 description 2
- 102100004239 SOD2 Human genes 0.000 description 2
- 108050002485 Sirtuins Proteins 0.000 description 2
- 102000011990 Sirtuins Human genes 0.000 description 2
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 229960005322 Streptomycin Drugs 0.000 description 2
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003078 antioxidant Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000000923 atherogenic Effects 0.000 description 2
- 230000000740 bleeding Effects 0.000 description 2
- 231100000319 bleeding Toxicity 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001112 coagulant Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 231100000024 genotoxic Toxicity 0.000 description 2
- 231100001045 histological change Toxicity 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 230000002297 mitogenic Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neurons Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000004923 pancreatic tissues Anatomy 0.000 description 2
- 239000003614 peroxisome proliferator Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000212 subchronic toxicity study Toxicity 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002723 toxicity assay Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2R,3S,4S,5R)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2S,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- KJYIVXDPWBUJBQ-UHHGALCXSA-N 11-Dehydrothromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(=O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O KJYIVXDPWBUJBQ-UHHGALCXSA-N 0.000 description 1
- ASJSXUWOFZATJM-UHFFFAOYSA-O 2-(2,5-diphenyl-1H-tetrazol-1-ium-3-yl)-4,5-dimethyl-1,3-thiazole Chemical compound S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)[NH2+]C(C=2C=CC=CC=2)=N1 ASJSXUWOFZATJM-UHFFFAOYSA-O 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 229940035674 ANESTHETICS Drugs 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 108010082126 Alanine Transaminase Proteins 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 108009000409 Autophagy Proteins 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000024678 Bcl-2 family Human genes 0.000 description 1
- 108091011726 Bcl-2 family Proteins 0.000 description 1
- 230000037227 Blood Loss Effects 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N Bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000004981 Coronary Disease Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 1
- 206010061835 Diabetic nephropathy Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 102100010966 GPT Human genes 0.000 description 1
- 108060003412 GRP Proteins 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- JGBUYEVOKHLFID-UHFFFAOYSA-N GelRed Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108090000353 Histone deacetylases Proteins 0.000 description 1
- 102000003964 Histone deacetylases Human genes 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 229960002869 Insulin Glargine Drugs 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 210000004153 Islets of Langerhans Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 210000003470 Mitochondria Anatomy 0.000 description 1
- 206010027906 Monocytosis Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N N-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical group O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 101700071069 NDP Proteins 0.000 description 1
- 102000037080 NR1 subfamily Human genes 0.000 description 1
- 108020001305 NR1 subfamily Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N Nicotinamide adenine dinucleotide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 210000003463 Organelles Anatomy 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 108009000578 Oxidative Stress Proteins 0.000 description 1
- 102000017946 PGC-1 Human genes 0.000 description 1
- 101700030590 PGC-1 Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000002824 Peroxisome Anatomy 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001312569 Ribes nigrum Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101700050776 SIRT1 Proteins 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960003942 amphotericin B Drugs 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 210000001557 animal structures Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000003178 anti-diabetic Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 230000006877 autophagy Effects 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 201000002393 blood protein disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 230000000711 cancerogenic Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- 230000002559 cytogenic Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 231100000463 ecotoxicology Toxicity 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 231100000584 environmental toxicity Toxicity 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004065 mitochondrial dysfunctions Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 210000000663 muscle cells Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000027739 nuclear receptors type II Human genes 0.000 description 1
- 108091008008 nuclear receptors type II Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 230000037050 permeability transition Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 231100000239 photoclastogenicity Toxicity 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229930014565 phytoalexin Natural products 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000031055 positive regulation of mitosis Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000003331 prothrombotic Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002784 sclerotic Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 150000003436 stilbenoids Chemical class 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 231100000195 subchronic toxicity Toxicity 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
Abstract
The invention elates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of Formulation I, and its method on in vitro and in vivo systems. Formulation I and its variables can be used to treat hyperglycemia, gout, dyslipidemia, obesity, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, pre-diabetes, arrhythmias, myocardial infarction, renal and pancreatic complications, cardiovascular complications.
Description
TECHNICAL FIELD
The présent invention focuses on définition of pharmaceutical compositions and proposed method for the treatment of metabolic syndrome, diabètes mellitus and aging. Compounds and compositions of natural origin are disclosed in the description. More particularly, this invention relates to a method of treating diseases based on the use of responses developed in cellular Systems and mammalian organisms (animais and humans) with the pharmaceutically acceptable doses of the compounds being part of Formulation I, such as metabolism control and cell growth.
BACKGROUND OF THE INVENTION
Metabolic syndrome, formerly known as syndrome X, is an intermediate state between normal metabolism and type 2 diabètes mellitus. It is an emerging épidémie that has been defined as a sériés of metabolic risk factors predisposing people to heart and coronary disease and chronic rénal failure, among other disease states. Metabolic syndrome is associated with abdominal obesity, atherogenic dyslipidemia, hypertension, proinflammatory and prothrombotic state, with or without glucose impairment,
i.e. diabètes. Symptoms are related to high triglycéride levels, low high-density lipoprotein levels, increased blood pressure or hypertension and increased glucose levels, and inflammation symptoms. Each of these characteristics is a significant risk factor for development of vascular dysfunction and cardiovascular, rénal and hepatic diseases (Eckel R. H et al in Lancet, 2005, 365: 1415) Metabolic syndrome increases the risk of prématuré death, therefore, effective and affordable strategies to help reduce cardiometabolic alteration factors and to control the syndrome are important goals to benefit a large population being under high risk.
Currently the main approaches to treat people with metabolic syndrome are aimed at reducing the underlying causes, treating hypertension and other cardiovascular risk factors, and control insulin résistance. Treatment of metabolic syndrome includes lifestyle changes, along with drug treatment. In addition to treating metabolic syndrome implementing dietary guidelines and adéquate physical activity to address the many underlying mechanisms of metabolic syndrome, a sériés of médications designed to control the altered levels of métabolites associated with manifestation of the disease state hâve been developed, incorporating varions biologically active nutritional compounds aimed at the same goal. Functional knowledge of nutrient impact, especially amino acids and polyphenols in diet on different molecular targets, makes possible to develop a composition of naturally occurring compounds to treat obesity, metabolic syndrome, diabètes and aging. Some concepts and patents related to the subject of the présent invention are described below.
Lodder and Cassis (Lodder R A and Cassis L A in US Patent 2015/9060962 Jun. 23, 2015) patented pharmaceutical compositions comprising D-tagatose with or without stilbene or stilbenoid, or dérivatives thereof, to prevent or treat atherosclerosis, metabolic syndrome, obesity or diabètes. Silbenoids such as resveratrol (3, 5, 4-trihydroxy-trans stilbene) which is a type of natural phénol and a phytoalexin produced in plants was applied during the response to pathogen attack or other injury. Large amounts of resveratrol can be found in different types of berries, grapes, cranberries, etc. (Fremont in Life Sci, 2000, 66: 663). Prior to that patent, Baur et al. (J. A. Baur et al in Nature, 2006, 444 (7117). 337) and Do et al. (Do G M et al in Biochem Biophys Res Commun, 2008, 374 (1). 55) reported the effect of resveratrol to improve health and survival of mice on diets high in calories, control alterations in cholestérol levels, among other capabilities. Another compound chemically related to resveratrol, pterostilbene known as 3,5-dimethoxy4'hydroxystilbene, is characterized by displaying similar effects to resveratrol.
Sirtuins are enzymes with histone deacetylase and some transcription factor activity that regulate metabolic pathways involved in development of cardiovascular diseases, aging and stress résistance (Jiang W J Biochem. Biophys. Res. Commun., 2008, 373 (3): 341). It is considered that resveratrol directly or indirectly activâtes SIRT1 (NAD-dependent sirtuin-1 deacetylase) and PGC-1 (gamma receptor coactivator activated by peroxisome proliferator), and affects functioning of mitochondria (Lagouge M. et al in Cells, 2006, 127 (6): 1109; Alcain F J and Villalba J M in Expert Opin Ther Pat, 2009, 19 (4) : 403; Beher D. et al in Chem Biol Drug Des, 2009, 74 (6) : 619). In cells treated with resveratrol, there is an increase in SOD2 (MnSOD) action (superoxide dismutase 2, mitochondrial, also known as manganese-dependent superoxide dismutase) reducing superoxide, which involves résistance to mitochondrial dysfunction, permeability transition, and death by apoptosis in several diseases. It has been found that resveratrol also acts as a GPER agonist (GPR30) (G protein-coupled estrogen receptor 1, also known as G protein-coupled receptor 30) (Prossnitz E. R. and Barton M. in Mol. Cell. Endocrin. 2014, 389 (1-2): 71). A possible action mechanism of resveratrol can be attributed to autophagy modulation (autophagocytosis—aimed at eliminating dysfunctional mechanism components) (Ghosh H. S. et al in PLoS ONE, 2010, 5 (2) . e9199) . Laboratory animais hâve shown the positive effects of resveratrol as an antidiabetic treatment (Baur J A et al in Nature, 2006, 444 (7117) : 337; Lagouge M. et al in Cells, 2006, 127 (6) . 1109.). This compound acts as PPAR gamma agonist (gamma receptor activated by peroxisome proliferator (PPAR-γ or PPARG), also known as glitazone receptor, or R1C3 (nuclear receptor subfamily 1, group C, member 3) is a type II nuclear receptor), considered as a pharmacological target for treatment of type 2 diabètes (L. Wang et al in Biochem Pharmacol 2014, 92 (1) : 73) . Peroxisomes are organelles that may cause disease and aging processes while not properly functioning. The ability to stimulate the activity of endothélial nitric oxide synthase (eNOS) and inhibit platelet aggregation is attributed to resveratrol (Vita J.
A. Duffy S J in Curr Opinion Lipid, 2003, 14 (1). 21; Olas
B. and. Wachowicz B. in Platelets, 2005, 16 (5): 251).
Plant extracts may be considered as antioxidant source, resveratrol analogs. US Patent 2016/9,278,104, Mar. 8, 2016 for Romero T., established the use of Nelumbo nucifera leaf extract to reduce and/or eliminate one or more risk factors associated with metabolic syndrome. The composition considers the presence of créatinine—a nitrogenated organic acid much like amino structure located in muscles and nerve cells of different living organism. It is synthesized naturally in the liver, pancréas and kidneys from amino acids such as arginine, glycine and méthionine at a rate of one gram of creatine per day. It is considered as an immédiate and direct vector to transport ATP and supply energy to muscle myofibrils.
Gokaraju G. R. et al., in US Patent 2016/9,241,964, Jan. 26, 2016 establishes the composition of phytochemical fractions for pharmaceutical use or as a dietary supplément derived from Sphaeranthus indicus and/or Garcinia mangostana. The composition is applied for obesity, metabolic syndrome, diabètes and other metabolic disorder control, prévention and treatment, and also to regulate energy expenditure, prévention of coronary artery and abdominal aorta atherosclerotic plaques, increase insulin sensitivity, control of glucose levels, triglycéride levels and balance glucose levels in mammals. Extracts which contain amino acids among other components are mentioned; however, those are not disclosed.
It is widely known that amino acids are an important part in the synthesis of various proteins involved in human metabolism. This invention is considered to be the reason for which the composition can be selected for the treatment and prévention of metabolic syndrome, obesity, diabètes, and aging.
Varfolomeev S. D. and Gurevich K. G. (in Russian
Chemical Bulletin, 2001, 50 (10): 1709) performed biocomputer analysis demonstrating that glycine amino acid is most frequently found (37.5%) in defined positions of primary sequences in different enzyme familles. Authors attributs this property to the rôle of glycine in enzyme architecture: being an amino acid with the chiral atom which allows movement and flexibility to protein chains. This demonstrates the importance of glycine for metabolism. The following 5 amino acids are aspartic acid (12.9%), cysteine (6.7%), histidine (6.2%) and arginine (5.5%). Cysteine is responsible for maintaining the conformation of various proteins due to the formation of sulfur bridges. Histidine and arginine like aspartic acid are common in enzyme active sites by playing a rôle in the catalytic site as core agents and electrophiles.
In the case of arginine (Wu G. A. B. et al in Curr Opin Clin Nutr Metabol Care, 2000, 3 (1) : 59) its ability to help reduce insulin résistance is reported, allowing a decrease in the amount of insulin in diabètes treatments, increase glucose tolérance and improve insulin sensitivity in type 2 diabètes mellitus.
Cysteine is the limiting substrate for glutathione synthesis—responsible for protecting cells against viruses, bacteria, fungi, carcinogens, as well as against other disease states. Oral cysteine applied without any other components is not recommended because it is rapidly catabolized to the gastrointestinal tract passing to a toxic state. Cysteine has antioxidant properties, due to the ability of thiols to participate in redox reactions. These cysteine antioxidant properties are mostly expressed in tripeptide glutathione. Availability of oral glutathione is insuf f icient, thus it must be biosynthesized from the amino acids that constitute it—cysteine, glycine and glutamic acid, from which cysteine is the limiting substrate. Different trials supplemented by laboratory tests hâve shown that aging is directly associated with a progressive decrease in plasma cysteine and glutathione intracellular concentration. This decrease leads to agerelated oxidative stress. Cysteine supplémentation above normal diet reduces the various aging processes by helping the bone and muscular Systems, reducing inflammation and levels of cytokines (L. Wang et al. In Biochem. Pharmacol. 2014, 92 (1) : 73) .
Control of cellular prolifération is essential to the proper functioning of any organism. Alteration of this régulation is the cause of diseases such as cancer—with unlimited and uncontrolled cell prolifération due to genetic mutations. Conversely a loss of the ability of cell prolifération is one of the factors causing aging.
Extracellular control of cell division may be performed by cell cycle mitogens, several growth factors as well as by survival factors. Mitogens are proteins that stimulate cell division, counteracting intracellular stop mechanisms (Rb) that block cycle progression.
The growth of any organism or organ dépends on both growth and cell division. If cells should be divided without growing, they would become smaller each time. Growth factors stimulate cell growth (cell mass increase) by promoting synthesis and inhibition of proteins and other macromolecules. Cell growth does not dépend on cell cycle. For example, nerve and muscle cells grow especially after cell division. Like most mitogens, growth factors bind to cell surface receptors which then activate different intracellular signaling pathways, which may induce: increased protein synthesis or a decreased protein dégradation. Ail thïs wïll lead to cell growth.
Survival factors promote cell survival by suppressing intracellular death programs or apoptosis. These signal need from other cells for survival help cells survive only when and where required. Neurons for example, are produced in excess and they compete each other in obtaining growth factors and those with the largest amount will survive. As mitogens and growth factors, survival factors tend to bind to cell membrane receptors which activate intracellular signaling pathways that inhibit cell death, usually by regulating proteins belonging to the Bcl-2 family. Some
survival | factors are IL-3, SCF, | IGF- | 1, which | are | mainly |
secreted | by the liver in response | to | signais | from | growth |
hormone | (GH) . | ||||
Based on the above and for | the | purpose | of | solving | |
above mentioned problems, the object | of présent invention |
is to provide the use of a formulation consisting of : resveratrol, glycine, arginine and cysteine, setting the range of component concentrations based on the study of Artemia salina model. What is patented in this case is the use of the formulation, and the method of its application for treatment of diseases. The formulation has the novel effect to stimulate prolifération of cell cultures and lymphocytes in vitro, without genotoxicity evidence, revealing the ability to decrease formation of viscéral fat observed in healthy laboratory animais induced to diabètes, controllability of glycemia index with less insulin or without insuline shown in the model of alloxan-induced diabètes, cytoprotective effect of treatment presented in the pancréas of animais treated with alloxan, correction of symptoms of metabolic syndrome and obesity in patients treated during a 6-month period. In the examples described below it is demonstrated that the formulation has a revitalizing ingrédient that act at the level of energy production, restoration of oxygen metabolism and réactivation of various enzymatic cycles related to sugar, fatty acid and cholestérol metabolism, increasing the energy available in the cells for increased functionality and vitality expressed in terms of increased prolifération. Examples demonstrate that when said formulation is applied in animais and humans, altered functions related to négative factors of diabètes, obesity and/or metabolic syndrome are normalized. According to these examples, treatment with the designed formulation is a method to control aging, metabolic syndrome, obesity and diabètes.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. Toxicity expressed in terms of mortality of A. salina, shown by resveratrol (R), glycine (G), arginine (A) and cysteine (C) components applied at different concentrations.
FIG. 2. A. salina viability in the presence of different concentrations of Formulation I.
FIG. 3. Number of lymphocytes (top) and their viability (bottom) in samples treated with Formulation I at different concentrations.
FIG. 4. Test genotoxicity of Formulation I applied at different concentrations in mononuclear cells (lymphocytes) above,—electrophoresis plates; in the middle,—percentage of integrated DNA (head) (*p<0.05 vs. White with RPMI); below,—the calculation based on the results of electrophoresis sample end (*p<0.05 vs. positive control with 0.1 mM H2O2).
FIG. 5. Effect of different concentrations of Formulation I in viability of human embryonic kidney cell line HEK-293 cell culture (above) and African green monkey (Vero) kidney cell culture.
FIG. 6. Graphical représentation of the values for blood chemistry parameters in animais with and without treatment with Formulation I: above—male rabbits; below, — male rats, prier to application of the single dose and after 14 days application of 1000 mg/Kg.
FIG. 7. Weight change dynamics (top) and glucose concentration (capillary glycemia) (below) in different groups of lagomorph animais subjected to treatment: I— insulin and 50, 70, 90 mg/kg—in Formulation I dose.
FIG. 8. Weight change dynamics (top) and glucose concentration (capillary glycemia) (below) in different groups of rodents subjected to treatment with: I—insulin and 50, 70, 90 mg/kg—in formulation I dose.
FIG. 9. Comparison of histological changes observed at pancréas level in rabbits with induced diabètes, treated and untreated with Formulation I and insulin. Above, — Histological section of tissue removed from female pancréas treated only with insulin, complété destruction of the organ demonstrated: only adipose tissue with congested blood vessels and two lymph nodes with reactive changes were found, deliberate search was performed without identifying feasible pancreatic tissue. Below—Histological section (10χ) of female pancreatic tissue treated only with Formulation I (left), identifying the excretory portion pancréas préservation acini without histologie changes associated, however, endocrine component is not identified (islet cells); Image (40*) corresponds to an approach to integrating pancreatic excretory portion (acini) (right).
FIG. 10. Comparison of histological changes observed at kidney level in induced-diabetes rabbits treated and untreated with Formulation I and insulin. Above— Histological section of rénal tissue of treated female only with insulin: at glomerular level with mesangial cell increase without atypia, focal thickening of blood vessel wall without formation of sclerotic nodules, which corresponds to early diabetic nephropathy characterized by mesangial slight increase (left); male kidney eut treated only with insulin, with good préservation of the bone cortex, abundant glomeruli with good cellularity with slight congestion, no sclerosis changes. In the tubular component there are changes by coagulative necrosis and nuclei pyknosis (right). In the middle-Histological female kidney eut treated with insulin and Formulation I to 90 mg/kg, showing good bone cortex conservation, identifying abundant glomeruli with good cellularity with very slight congestion, no sclerosis changes. In the tubular component initial changes are seen by coagulative necrosis and pyknosis nuclei. Below,—histological section of male congestive kidney tissue under treatment with Formulation I to 70 mg/kg (left,—10χ) with érythrocyte extravasation (microscopie bleeding) at medulla and cortex, identifying structures showing increased glomerular mesangial cells without atypia, slight congestion; drawing corresponds to an approach of congestive glomeruli (right—at 40*).
DETAILED DESCRIPTION OF THE INVENTION
Characteristic details of the invention consist of defining Formulation I, defining its application, biological effects in living Systems at different levels (cellular, healthy animais or diabetes-induced, human organism). The following paragraphs describe the purpose of defining the invention, illustrate the novelty and utility of présent invention, but without limiting the scope thereof and not intended to unduly limit it. The following examples are based on tests conducted to define Formulation I, as well as test their effects on in vitro and in vivo Systems.
Description of the formulation comprising the basic compositions and préparation in the light of the invention, according to présent invention is shown in Table 1.
Table 1 FORMULATION I | ||
Dose Size | 5 g - 17 g | |
Dose per bag | 1 bag | |
Bags per box | 90 | |
Component | Dose-Range (Min- Max) | Purity (%) |
Glycine* | 3,000-7,000 mg | 98.5-101.5% |
L-Arginine HCl* | 300-5,000 mg | 98.5% |
L-Cysteine HCl* | 200-2,500 mg | 98.5-101.5% |
Resveratrol* | 100-2,500 mg | 98% |
*Daily values in diet are not established Approximate amounts for a 70 kg weight individual |
The composition accordinc; to claim 1 further characterized in that comprises one of the embodiments of the potential combinations of compounds of présent invention with higher therapeutic effect for advanced disease cases, as well as integrating an embodiment of nanoparticles decreasing the dosage régime.
Table 2 | ||
Dose Size | 6 g-19 g | |
Dose per bag | 1 bag | |
Bags per box | 90 | |
Component | Dose-Range (Min- Max) | Purity (%) |
L-Glycine* | 3,000-7,000 mg | 98.5-101.5% |
L-Arginine HCl* | 2,000-5,000 mg | 98.5% |
L-Cysteine HCl* | 1,000-2,500 mg | 98.5-101.5% |
L_Methionine* | 500-1,500 mg (500 mg 98.5-101.5% in nanoparticles) | 98.5-101.5% |
Vitamiη B6 (Pyridoxin-HCl) | 500-1,500 mg | 98.5-101.5% |
Resveratrol* | 500-1,500 mg (500 mg in nanoparticles) | 98% |
*Daily values in diet are not established **20 mg is 100% of daily requirement |
Example 1
The assay was performed to evaluate the toxicity of components proposed for Formulation I (resveratrol, glycine, arginine and cysteine), on Artemia salina nauplii. Artemia salina is a crustacean sensitive to a wide range of compounds with Joiological activity and very different chemical structures. Michael et al. (Michael A. S. et al in Science, 1956, 123: 464) and Vanhaecke et al. (Vanhaecke et al in Ecotoxicol Environ Saf 1981, 5:382) proposed its use for toxicity testing. It is a test that allows conducting practically and economically toxicity studies of different nature substances. There has been very good corrélation with other spécifie cytotoxicity tests. This model is accepted by the FDA (Food Drug Administration) and EPA (Environmental Protection Agency in 2002), as a test for evaluating the toxicity and ecotoxicity of pharmaceutical and/or food products.
The assay was performed according to the method standardized using different dilutions of each of Formulation I components. In an Artemia salina hatcher, 0.5 g cysts of Artemia salina were hatched in artificial seawater at 37 g/L at a température of 27° C. with constant aération for 24 h. In every 5 wells out of a 96-well plate, 0.1 mL of artificial seawater (37 g/L) was applied with a single-channel pipette with ten nauplii, separated from the hatcher and counted one by one to achieve an exact séparation of 10 nauplii. From a 2000 ppm stock solution of resveratrol, glycine, arginine and cysteine serial dilutions were made. Using a multichannel micropipette, 0.1 mL of the solutions prepared in the plate were added, achieving a final concentration of 62.5, 125, 250, 500 and
1000 ppm per five wells of nauplii. For blank samples, 10 untreated nauplii were placed in a 0.2 mL volume of artificial seawater (37 g/L) . The microplate was incubated at 25° C. for 24 h. After incubation period, A. salina nauplii alive and dead were counted with a stereoscopic microscope and % mortality was determined. Toxicity was expressed as percent mortality of A. salina nauplii: 0-10% non-toxic, moderately toxic 11-50%, 51-90% highly toxic and 100% extremely toxic, considering the Gualdron et al, scale. (Gualdron R. et al in Chem Rev. Col. Farm, 1997, 26: 15 to 19). Component solutions of Formulation I were 5-fold tested. Data were analyzed with the Statistical Package Graph Pad Prism version 6, by analysis of variance (ANOVA) test and Tukey multiple comparisons (p<0.05).
The results of data analysis were expressed as the istandard déviation average and are presented in FIG. 1. Glycine, arginine and cysteine are toxicity free at any of the tested concentrations, thus suggesting that if toxicity may occur, it can only be just above 1000 ppm (FIG. 1). For resveratrol, in the 62.6 ppm solution a 38% mortality (moderate toxicity) was présent, while LC50 (léthal concentration to 50% nauplii) was estimated as 89.48 ppm, suggesting that from this concentration resveratrol is highly toxic. This data is taken into account to define Formulation I: resveratrol concentration was selected below CL50; in the case of amino acids any concentration below 1000 ppm may be used.
Example 2
As Formulation I exemplified herein the following composition of the biologically active components is considered: 5.7 mg of resveratrol, 74.3 mg glycine, 5.7 mg arginine and 2.9 mg of cysteine/weight kg or solvent kg, for use in mammals (including humans) or cell cultures, respectively. The resveratrol concentration was selected considering the results defined in Example 1, i.e., about 15 times less than its CL50 to prevent the toxicity manifestation. Arginine weight was taken équivalent to resveratrol, cysteine approximately 2 times less than resveratrol, and glycine as 13 times weight of resveratrol. Formulation I is an example of the mixture of biologically active components, which should not limit the scope of the invention. The Formulation I dose of 88.6 mg/kg is defined in this case.
Using Formulation I the assay similar to that described in Example 1 was performed to define the range of toxicity thereof. Results are presented in FIG. 2. It is shown that at a concentration lower or equal to 500 ppm, 100% of A. salina nauplii are kept alive and to 1000 ppm of Formulation I only 58% are alive. This indicates that according to model applied Formulation I is not toxic to a concentration up to 500 ppm, but at higher concentrations up to 1000 ppm a moderately toxic behavior is shown. This demonstrates that by using Formulation I, the concentration thereof may be varied in a wide range of concentrations and doses considering the absence of toxicity.
Example 3
Formulation I was applied to a test to détermine their effects on human cells, i.e. to stimulate growth effects (mitogenic effect) or cause cell death (cytotoxic effect).
For the assay, a biological in vitro System using mononuclear cells culture from peripheral blood mononuclear cells—peripheral human lymphocytes was used. The System was selected because they form from 25 to 35% of leukocytes and they are the main immune response promoting cells since they recognize foreign antigens and activate cellular immune response mediators, causing prolifération or suppression phenomena before endogenous or exogenous stimuli. These cultures are widely used in research to evaluate the effects of various compounds (Marti-Centelles R. et al in J. Med Chem Eur, 2015, 103: 488) . The effects on cell prolifération were assessed and LC50 and LC100 (concentrations that decrease the amount of living cells at 50 and 100%, respectively) of Formulation I on human lymphocytes in vitro were determined. As a positive control the test with concanavalin A (Con A) was performed, which is a globular plant-origin protein that induces mitosis in lymphocytes causing clonal prolifération (Ganem and Martin Gonzalez Baez FAO. in Universo Diagnôstico, 2000, 1 (1):1). Assay with RPMI-1640 (medium without treatment) was performed as blank. The effect of Formulation I, applied in a concentration range from 200 to 2000 ppm, was assessed by counting total number of cells and dead cells stained with trypan blue dye.
IL of RPMI-1640 medium culture (SIGMA) was prepared supplemented with 10% FBS, adding 1 ml of 1χ solution streptomycin and amphotericin B (SIGMA), sterilized through stérile filtration units (Corning) using 0.22 micron membranes. Serial dilutions from a stock solution of 2000 ppm of Formulation I at 200, 400, 600, 800, 1000 and 2000 ppm were prepared.
mL of peripheral blood from healthy volunteer donors by venipuncture were obtained, which was collected in plastic tubes containing EDTA as an anticoagulant. Then, mononuclear cells from peripheral blood (PBMC) isolated by a Ficoll-Hypaque density gradient (Sigma-Aldrich) by centrifugation at 1200 révolutions per minute (rpm) for 30 minutes at 25° C. were obtained. PBMC were washed twice with PBS lx, cell pellet finally was resuspended in culture medium. PBMCs consist of monocytes and lymphocytes. Monocytic cells are characterized by being adhèrent cells which lack proliférative potential. Otherwise they represent the lymphocytes, which are cells in suspension, able to proliferate after an endogenous or exogenous stimulus. To separate monocytes from lymphocytes, obtained PBMC were horizontally cultured in 25 cm<3 >boxes so that monocytes adhéré to the surface over a period of 5 hours at 37° C. with humidified atmosphère, in a 5% CO2 atmosphère. After incubation time, lymphocytes—the cells remaining in suspension were separated in stérile 1.5 ml tubes and centrifuged at 1200 rpm for 10 minutes (Eppendorf Centrifuge 5810-R), then 1 mL of culture medium was added to cellular package. A suspension of 500,000 cells/mL was prepared in Eppendorf tubes, to which were added different concentrations of Formulation I (200, 400, 600, 800, 1000 and 2000 ppm) adding a 1.25 mg/mL positive control of concanavalin A—an inducer of cell prolifération and blank— untreated cells, the culture medium was added. The samples were incubated at 37° C. in humidified atmosphère with 5% CO2 for 48 hours, sufficient for lymphocytes to complété cell division showing a similar positive control prolifération (Con A) by the product or causing cellular toxicity otherwise. Upon terminating incubation, Eppendorf tubes which contained the different samples were centrifuged at 1200 rpm for 10 minutes, the supernatant decanted, and the cell pack was resuspended in 1 mL of
RPMI-1640.
Optical light microscope with 40* objective was used. Cells were counted with Neubauer chamber using 0.05 mL suspension of each resuspended samples in 0.4 mL of PBS lx and 0.05 mL of trypan blue. The assay was performed in triplicate in three independent events. The results were analyzed by the variance analysis test (ANOVA) with SPSS version 16 and then Dunnet ' s test was applied to discern whether a différence between control and experimental
treatments was significant. | présent, | taking values of | p<0.05 | as |
FIG. 3 | shows the | test results. The | effect | of |
Formulation | I | applied | to 200 ppm to increase | the |
concentration | of | cells is apparent (number of | cells | per |
milliliter) to 15% significantly (p<0.05) when compared to the blank untreated: 6,372,333 and 5,518,333 cel/mL, respectively. As concanavalin A which counted an increase in the number of cells to 65% to obtain 9,101,667 cells/mL (FIG. 3) confirming its mitogenic activity. On the other hand, in the presence of concentrations of 1000 and 2000 ppm of Formulation I a decrease in cell number: 4,291, 667 and 3,540,333 cells/mL, respectively was observed.
The percentages of relative cell viability (VCR) were calculated and found that in the presence of concentrations of 200, 400 and 600 ppm, 97% of the cells were alive as in Blank and positive controls. From 800 ppm, as well as 1000 and 2000 ppm of Formulation I cell viability of human lymphocytes significantly decreased (FIG. 3 below), with the following percentages of 90.58%, 84.38% and 64.96% respectively. LC50 and LC100 for Formulation I were estimated at 2,726.8 ppm and 5,165.82 ppm, respectively. This value is significantly higher to that detected in the test with A. saline and proves that Formulation I lacks cytotoxicity at the applied doses. At doses of 50-90 ppm Formulation I is not cytotoxic according to both tests. These doses are in the range of stimulating lymphocyte prolifération confirming its important effect for the method of aging treatment.
Example 4
The following example shows that the proliférative effect and inhibitory effect shown in Example 3 are not related to the level of DNA (deoxyribonucleic acid) damage. For this purpose the cornet assay, a rapid, sensitive, simple and quantifiable method to measure the degree of damage at the level of deoxyribonucleic acid (DNA) was developed. This assay is accepted as a tool to investigate compounds or deleterious effects on DNA repair (Azqueta A. and A. R. Arch Toxicol Collins, 2013, 87: 949). It is used in Systems in vivo, in vitro, ex vivo in different scientific disciplines for genotoxicity tests, preclinical and clinical studies, ecotoxicology genetic testing, cytogenetics, photogenotoxicity, and the like.
Mononuclear cells and human peripheral blood lymphocytes were separated according to the same methodology described in Example 3. By using culture medium cell concentration was adjusted to 1χ10<6 >cells/mL. Cells obtained were seeded in Eppendorf vials at a density of 3><10<4 >cells/mL and incubated at 37° C. and 5% CO2 for 24 hours to stabilize. Subsequently vials were centrifuged at 1250 rpm for 5 min at 22° C. and supernatant was replaced with solutions of Formulation I to 7.81, 15.63, 31.25, 62.50, 125, 250, 500, and 1000 ppm (n=4 each). Blank test cells were resuspended in culture medium (n=8) and others with 0.1 mM hydrogen peroxide (positive control, n=8). Cells were incubated for 24 h to be later precipitated by centrifugation at 1200 rpm for 5 min and treated with 0.1 mL trypsin (0.25%) for 3 min at 37° C. and 5% CO2. Cells were resuspended in 1 mL of RPMI 1640 medium and centrifuged again at 1200 rpm for 5 min, the supernatant was discarded and the cells were incubated with 1 mL of lysis solution (NaCl 2.5 M, Na2EDTA 100 mM, Tris HCl 10 mM, and 1% Triton) at 4° C. for 24 h. After 24 h, vials were centrifuged at 1200 rpm at 4° C. The supernatant was discarded and cells were treated with 1 ml of neutralization buffer (0.4 M Tris pH 7.5) for 5 min at 4°
C. Vials were centrifuged at 1200 rpm for 5 min at 4° C., cells were resuspended in 0.02 mL of loading buffer (bromophenol blue 0.25%, glycerol 50%, Tris-HCl 10 mM and 50 mM Na2EDTA). Agarose gels were prepared by dissolving 1% in saline phosphate buffer (PBS) in a heating plate at 100° C. Once dissolved, and at 60° C., 0.01 mL Gelred (fluorescent dyeing DNA compound) was added. This mixture was placed in a horizontal electrophoresis chamber for 60 min. The lysed cells were loaded on agarose gels and incubated with the electrophoresis solution (1 mM Na2EDTA and 300 mM NaOH at pH 13.5) for 20 min at 4° C. The electrophoret ic running was performed at 25 V and 300 mA for 30 min at 4° C. Gels were removed from the electrophoresis chamber and revealed in a fluorescent signal analysis chamber. The generated images were acquired with a high resolution digital caméra (FIG. 4, above) and analyzed with ImageQuant TL v8.1 software. The area of the cornet head representing intact DNA was quantified by densitométrie analysis and plotted as percentage versus the négative control (culture medium) (FIG. 4, in the middle). The tail of the cornet representing the damaged DNA was measured in millimeters and represented as the percentage of the positive control (H2O2) . Data were expressed as meanlmean standard déviation (FIG. 4, below). Data obtained were analyzed by analysis of variance (ANOVA) using in case of any différence a post-hoc Tukey test using GraphPad Prism v6.0 software, at p<0.05.
Results (FIG. 4) show that human peripheral blood mononuclear cells treated with various concentrations of Formulation I in RPMI 1640 culture medium supplemented with 10% FBS showed no damage in dsDNA (dsDNA) . An apparent damage was not generated in the cornet head (intact DNA) (FIG. 4, in the middle). In contrast, hydrogen peroxide (0.1 mM) , known to exert genotoxic effects, shows the behavior in which a much more rapid dsDNA diffusion (FIG. 4, up and down) is detected, which is a genotoxicity indication, and due to this phenomenon the reading measuring area is much higher compared to Blank (FIG. 4, below). Behavior of samples treated with Formulation I was similar to the Blank, indicating that treatment with this for 24 h does not generate deleterious effects on mononuclear peripheral blood cell DNA (FIG. 4) . In addition, the genotoxic effect induced by hydrogen peroxide (Azqueta A. and A. R. Collins in Arch Toxicol, 2013, 87: 949) was reproduced indicating that under experimental conditions, methodology developed is sensitive and trustable. Formulation I causes effects on cell growth without generating deleterious effects on human mononuclear cell DNA.
Example 5
The effect of different concentrations of Formulation I was evaluated on the human embryonic kidney (HEK-293) cell line and the Vero cell line (African green monkey kidney cells), using a microdilution assay with 3-(4,5dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium (MTT) (Mosmann T. in J. Immunol Methods, 1983, 65 (1-2.) : 55) . MTT method, based on réduction of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide, is an assay that reflects the metabolic function of cells. MTT is a yellow dye reduced to formazan (blue dye) by mitochondrial dehydrogenases, which are part of the respiratory chain of viable cells (Hwa et al., 2015). It is used in a quantitative colorimétrie microdilution method applied for détermination of survival and proliférative capacity of mammalian cells (Mosmann T. in J. Immunol Methods, 1983, 65 (1-2) : 55) . It is a suitable in vitro test for evaluating cell prolifération and cytotoxicity because it is simple, efficient, economical, reproducible, sensitive, safe, and effective as to viable cell population.
Dulbecco's modified Eagle Minimum Essential culture Medium/F12 (DMEM/F12) was used, supplemented with 10% fêtai bovine sérum (FBS) and 1 mL of a mixture of antibiotics (200,000 IU of penicillin and 0.5 g streptomycin). A trypsin solution (Difco) 0.25% was prepared. Serial dilutions from a 2000 ppm stock solution of Formulation I and Triton X-100 as solvent DMEM/F12 were prepared. 1 mL of each dilution was prepared to obtain concentrations of 1.95, 3.91, 7.81, 15.63, 31.25, 62.50, 125, 250, 500 and 1000 ppm. Cells of each cell cultures were grown using DMEM/F12 25 cm<3 >culture plates until a confluent monolayer on the plate surface was obtained. Conditions used for cell culture were 37° C., humidified atmosphère with 5% C02. Confluent cell monolayer was lifted off 25 cm<3 >plates using 0.25% trypsin. This was done as follows: DMEM/F12 medium was removed, then the monolayer washed 1 to 3 times with saline phosphate buffer lx then added 0.5 mL of 0.25% trypsin, and the contents were incubated at 37° C. in humidified atmosphère with 5% C02 for 5 min. 3 ml of DMEM/F12 were added on the lifted cells, cells were resuspended with a 0.1-1 mL micropipette and placed in a 15 mL stérile conical tube, subsequently centrifuged at 1000 rpm for 5 min. DMEM/F12 was removed from conical tube. 3 ml of DMEM/F12 were added on cell pack, the cells resuspended, and a count was done in a Neubauer chamber. A cell suspension of 250,000 cells/mL was then prepared. 0.1 mL of the 250,000 cells/mL per well microplate cell suspension was added in ail wells of a 96-well microplate, the microplate was incubated at 37° C. in humidified atmosphère with 5% CO2 for 24 h. DMEM/F12 medium of each well was removed with vacuum, maintaining the monolayer at the bottom of each well, then 0.1 mL of each dilution prepared from Formulation I and Triton X-100 (1.95, 3.91, 7.81,
15.63, 31.25, 62.50, 125, 250, 500, 1000 and 2000 ppm) was added. Furthermore 8 wells were left with untreated cells used as control for cell viability (cell culture medium with no treatment—Blank) , to which 0.1 mL of DMEM/F12 was added. Subsequently the microplate was incubated at 37° C. in humidified atmosphère with 5% CO2 for 24 h. Then the DMEM/F12 medium was removed with the samples of Formulation I and Triton X-100, the wells were washed once with phosphate buffered saline. 0.02 mL was added to a MTT solution at 5 mg/mL and the content was incubated at 37° C. for 2 h, to conduct a complété réduction process of MTT to formazan by living cell mitochondrial dehydrogenases.
Subsequently MIT solution was removed, retaining the formed formazan salts, then they added 0.1 mL of isopropyl alcohol and the absorbance at 540 nm was read in a Synergy HT microplate reader with GEN 5 embedded software. In the calculation of cell viability percentage detected absorbance in wells with cells proliferated in untreated culture medium were considered 100% of living cells. The Formulation I solutions were tested in quintuplicate and positive control solutions were tested in triplicate. The trial was conducted in three separate events. LC50 data of Formulation I and Triton X-100 were estimated using the Graph Pad Prism version 6 Statistical Package, by Student's t test (p<0.05). Results of data analysis are expressed as the averageistandard déviation (FIG. 5).
It was shown that for Formulation I at concentrations lower than 500 ppm, stimulation of prolifération and mitochondrial activity of HEK-293 and Vero cell Unes was observed. HEK-293 line increase was 140% at 1.95 ppm and over 40% at 62.5 ppm concentration, while in the case of Vero cells only 10% compared to Blank. The results prove the effect of Formulation I to stimulate cell prolifération.
A dose-dependent cytotoxic effect was observed above 500 ppm since as Formulation I concentration was increased a decrease in cell viability (FIG. 5) was observed.
In both cell Unes, the positive control (Triton X100) showed a dose-depending effect, as a decrease in absorbance was observed by increasing the concentration of this substance, according to that expected as it is a cytotoxic compound, without any increase in viability (values greater than 100%), in any of the concentrations tested, but a decrease was detected in absorbance compared to Blank (with no treatment).
LC50 for Formulation I and Triton X-100 were estimated with values of 2,417.00165.77 and 764.10121.93 ppm for HEK293 cell line and 4,289.001289.90 and 42.8011.60 ppm for Vero cell line, respectively.
Results obtained prove that no cytotoxicity of Formulation I is observed at concentrations of 50-90 ppm range. At this dose cellular metabolism stimulation is observed. The observed phenomenon is similar to that described in Example 3 and demonstrates that Formulation I should be considered a growth and cellular metabolism factor-promoter.
Example 6
The effect of Formulation I was observed in healthy laboratory animais such as rodent and lagomorph models (Wistar rats and New Zealand rabbits) in the acute toxicity assay (single application, monitoring for 14 days) with high doses—higher than LC50 of A. salina assay described in Example 2 (1000 and 1350 mg/kg) and subchronic toxicity test (daily application twice a day for ninety-day doses of 50, 70 and 90 mg/kg). The same procedures of adding placebo (purified water), measurement of weight and glycemia were performed in parallel in négative control animais of each animal species.
In ail tests carried out on laboratory animais the treatment was orally administered in a weight-dependent measure, through orogastric cannula, after conventional feed consumption for rodents and lagomorphs (Commission of the European Communities in Off. J. Eur. Comm (L 383 A), 1992, 35: 110), respectively.
Animais were | kept in | individual cages | and | were | |
observed continuously for | the first | 24 | h | after | |
administration of | Formulation | I, continuing | the | observation | |
and intermediate | veterinary | care needed | for | each | test |
period being recorded in a logbook for any animal response. Body weight was determined and recorded at the beginning and end of the experiment. Also in case of rabbits, clinical laboratory tests were performed before and after each test: blood biometry, blood chemistry and activity of transaminase enzymes: aspartate aminotransferase (AST), alanine aminotransferase (TGP) and transpeptidase gamma glutamyl transaminase (GGT). In rats, these parameters were determined only at the end of testing to prevent blood loss. Finally, we proceeded with the euthanasia step to animais applying a sériés of anesthetics and potassium chloride (KC1). Subsequently, an organ and fundamental tissue macroscopie examination and necropsy was conducted, primarily including heart, kidney, spleen, pancréas, lung, liver, ovaries and testicles, according to each case. Samples taken were sent to carry out a histopathological study.
Maximum dose tested in the acute toxicity assay was 1350 mg/kg because the maximum volume applied by orogastric cannula is 1 or 3 ml for rodents and lagomorphs, respectively, and the use of higher doses led to obtaining a more viscous solution having difficulty passing the orogastric cannula. With the tested concentrations any death of laboratory animais was not observed, thus the LD50 value was not determined. Regarding the présent invention, it was shown that most of the evaluated parameters, including weight and activity of liver enzymes and blood biometry, showed no significant différence before and after treatment and compared with Blank (no treatment). However, in treated animais a decrease of glucose levels, a decrease of uric acid and cholestérol (FIG. 6) was appreciated. Because these parameters are related to metabolic syndrome, goût and diabètes, the test results indicate that the application of a single, Formulation I high dose leads to diminution of métabolite levels above and confirms the effect of use of this treatment for mentioned pathologies.
The same trend was observed in the case of the results of sub-chronic toxicity study. Decreased levels of glucose, cholestérol, uric acid, créatinine and liver enzymes was observed with the application of Formulation I at different doses. However, the statistically proven différence was only obtained with glucose control while changing other parameters is characterized by large standard déviation associated with individuality of subject in animais under study. Increased body weight in case of treated animais was lower than in the control. Furthermore, a repeatedly decrease in liver enzyme activity was observed which can be regarded as evidence of an effect of Formulation I to improve liver activity. The characteristic observation while performing autopsies was that animais treated with Formulation I in macroscopie évaluation faced significant muscle development and little development of body fat, in the same way they showed no hepatic steatosis. Ail this even though held for 90 days with very little movement inside the cages, i.e. without exercise and normal food intake according to weight and âge. These results also confirm that the application of Formulation I allows weight control mediated by a decreased amount of adipose tissue, glucose control and occasionally other characteristics of blood chemistry, without altering blood biometry and liver function in healthy mammals.
Example 7
In addition, the test in rats and rabbits with alloxan-induced diabètes was performed. In this test, as well as in the sub-chronic toxicity study, treatments were applied to three doses of Formulation I (50, 70 and 90 mg/kg). 5 groups of animais with treatments (insulin plus Formulation I at three mentioned doses, Formulation I at 70 mg/kg and insulin alone) were examined. Insulin glargine was administered subcutaneously at a dose of 0.7 U/kg in a single morning administration every 24 h.
Comparison of analysis results of blood chemistry in diabetes-induced rabbits at the beginning and end of the assay, found that even under treatment, glycemia are manifested at high level. An increase of urea and créatinine was observed, confirming kidney damage. However, in the case of rabbits treated with Formulation I, a decrease of levels of uric acid and cholestérol was observed.
Blood biometry results of rabbit blood before and after 21 days of application of treatments showed decrease in parameters related to the presence of monocytes and platelets and hemoglobin as a resuit of induced diabètes in animais. Monocytosis is a condition where an increase in the presence of a type of blank blood cells known as monocytes is présent. Monocytes are formed in the bone marrow and play an important rôle in the normal functioning of the immune System. Platelets are involved in blood clotting, helping to stop bleeding in case of injury. Observed changes indicate that during treatment of alloxaninduced diabètes, blood disorders or bone marrow were formed.
During clinical monitoring, several rabbit specimens showed weight loss associated with alterations in food intake and water (periods of anorexia with polydipsia), expected clinical data in any diabetic body. Some rabbits of the group of animais treated with 90 mg/kg Formulation I and insulin, a weight loss was not detected as ail other animais, even having evidence of weight gain, which shows that Formulation I shows organic protection. FIG. 7 (above) shows the trend of weight change in different groups of animais tested in the study. It is appreciated that the application of Formulation I leads to less weight loss. For groups treated with Formulation I and insulin, the greater weight gain is observed in the group with application of 90 mg/kg. This shows that the effect is dose-dependent.
Likewise, ail specimens handled with Insulin and Formulation I corroborated that it shows a hypoglycémie effect as in Examples 5 and 6. FIG. 7 (below) shows average values of capillary glucose levels in different days of treatment application. It is seen that the effect varies with different doses and is greater than 50 and 70 mg/kg compared to 90 mg/kg.
FIG. 8 (above) shows average values of weight change per group of rats with induced diabètes. In the case of group animais treated with pure insulin (I) a tendency of weight loss decrease is much more visible when compared to the other groups tested with study treatment. FIG. 8 (below) présents the average values of change of the glucose concentration (capillary glucose). For rats treated only with insulin an increase in the tendency for capillary glucose is seen up to 19 days of treatment. It is appreciated that in this period increased glucose is controlled more efficiently by only applying Formulation I to 70 mg/kg. The largest decrease of glucose levels in type 1 diabetic animais is observed for 70 mg/kg doses.
In clinical monitoring of rats with induced diabètes (type 1 diabètes), specimens of the groups treated only with insulin or Formulation I showed changes in feed intake and water (periods of anorexia with polydipsia), as in rabbits, these clinical data in any diabetic body are expected. However, the groups subject to treatment with Formulation I plus insulin did not show these clinical data so markedly, i.e. the application of treatments helped improve the quality of life of animais and joint management with insulin could improve clinical status of animais with diabètes showing the effect claimed in the présent invention.
Glucose levels in rats treated with 50 and 70 mg/kg of Formulation I plus insulin (Glargine) tended to normalization (FIG. 8, below). With regard to monitoring the group treated with 90 mg/kg and Insulin (Glargine), although the glycemia tended not to normalize in this short period of exposure, very similar data to those obtained in the lagomorph species with the same doses of treatment were observed (FIG. 7) . In both cases the results demonstrate that Formulation I shows organic protection from mammals with diabètes.
Comparison of blood chemistry analysis results among different groups of rats in the test prove that still under treatment, glycemias is manifested at high levels and high values of urea and créatinine were observed, confirming damage to kidneys. Blood biometry results show no significant différences between different groups tested.
In the macroscopie study after rabbit and rat autopsy with type I diabètes, groups treated with only supplément or insulin were observed to présent the most severe pancreatic alterations, having been confirmed in the histopathological sections (FIG. 9). Thus, alloxan as diabètes inducer, affects this organ and alteration was expected in ail animais. However, animais treated with Formulation I and insulin, showed no macroscopically détectable alterations. It is known the effect of resveratrol to increase the sensitivity of insulin receptors (Chachay V. S. et al in Br J Clin Pharmacol, 2011, 72 (1) : 27) . However, in the description of the présent invention Formulation I also demonstrates a further cytoprotective effect on animal organs and a recovery effect of damaged tissues when acting in presence of insulin.
According to histopathology results performed with samples of animais induced with diabètes, kidney damage (resuit consistent with blood chemistry analysis) is observed. However, in the specimens of groups treated with insulin and Formulation I, less kidney damage was observed than in specimens treated only with Formulation I or insulin alone. Together with the results of weight control and capillary glycemia, these results provide evidence that during the trial period (21 days) treatment applied with Formulation I along with insulin leads to protection of organs such as kidney and pancréas against changes caused by diabètes.
The examples shown herein confirm the ability of Formulation I to protect the organs of type 1 diabètes mammals against détérioration when applied with insulin. Furthermore, the ability to control blood sugar is noticed, which is enhanced in the presence of insulin, and the effect is seen to maintain weight gain, lowering cholestérol and uric acid.
Example 8
A 48-year man presented chest discomfort and subsequently diagnosed to hâve metabolic syndrome. Physical examination showed an obese person with a body weight of 87 kg, height 170 cm, with a BMI of 32 kg/m<2>. Blood pressure (BP) was 160/110 mm Hg, fasting plasma glucose (GA) was 150 mg/dL, triglycérides (Tg) of 215 mg/dL, total cholestérol (TC) 320 mg/dL, LDL-C 212 mg/dL, HDL-C 37 mg/dL, and HbAlc of 8.46%. The patient was subject to treatment with Formulation I as described in Example 2, three times a day after each food intake over the next 6 months. The form of application of Formulation I was prepared in a glass of water or juice suspension. Periodic évaluations were carried out to estimate affinity therapy and avoid any side effects. After this period of treatment with Formulation I, we proceeded to perform biochemical studies. Detected values were: GA 115 mg/dL, HbAlc 6.69%, TC 235 mg/dL, LDL-C
123.7 mg/dL, HDL-C 40 mg/dL, Tg 119 mg/dL and his weight dropped 74 kg. The level of 11-dehydro thromboxane B2 and platelet aggregation were reduced respectively by 75% and 90% compared to baseline. The response to therapy was 100%. With this procedure, the patient had a considérable modification of risk factors for metabolic syndrome.
Finally it must be understood that the use of glycine, cysteine, arginine and resveratrol to treat and prevent metabolic syndrome, diabètes, obesity, and as anti-aging treatment, is not limited to Formulation I and embodiments described above, and those skilled in the art will be trained by the teachings set forth herein to make changes in the treatment composition of the présent invention, the scope will be established solely by the claims.
REFERENCES | ||||
Alcain, | F. J. , | Villalba, J. M. | (2009) . | Sirtuin |
activators. | Expert | Opin Ther Pat. , | 19(4): | 403-414. |
doi: 10.1517/13543770902762893. PMID 19441923.
Azqueta, A., Collins A. R. (2013) . The essentiel cornet assay: a comprehensive guide to measuring DNA damage and repair. Archives of toxicology, 87: 949-968.
Baur, J. A. et al., (2006) . Resveratrol improves health and survival of mice on a high calorie diet. Nature, 444 (7117): 337-342.
Beher, D., Wu, J., Cumine, S., Kim, K. W. , Lu, S. C., Atangan, L., Wang, M. (2009) . Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des., 74 (6): 619-624. doi: 10.1111/j.1747-0285.2009.00901.x.PMID 19843076.
Chachay, V. S, Kirkpatrick, C. M. J., Hickman, I. J., Ferguson, M. , Prins, J. B., Martin, J. M. (2011) .
Resveratrol—pills to replace a healthy diet? Br J Clin Pharmacol. 72(1): 27-38 Commission of the European Communities. (1992). Annex to Commission Directive 92/69/EEC of 31 Jul. 1992 adapting to technical progress for the seventeenth time Council Directive 67/548/EEC on the approximation of laws, régulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. B.l Acute toxicity (oral). Off. J. Eur. Comm. (L 383 A) 35: 110-112.
Do, G. M. et al., (2008). Long-term effects of resveratrol supplémentation on suppression of atherogenic lésion formation and cholestérol synthesis in apo Edeficient mice. Biochem. Biophys. Res. Commun., 374(1): 55-59.
Duffy, S. J., Vita, J. A. (2003). Effects of phenolics on vascular endothélial function. Current Opinion in Lipidology, 14 (1) : 21-27. doi:10.1097/01.mol.0000052857. 26236.f2, PMID 12544657.
Eckel, R. H., Grundy, S. M. , Zimmet, P. Z. (2005). The metabolic syndrome. Lancet, 365: 1415-1428. Environmental Protection Agency (2002). Methods for measuring the acute toxicity of effluents and receiving waters to freshwater and marine organisms. Fifth Edition. U.S. Environmental Protection Agency Office of Water (4303T) 1200 Pennsylvania Avenue, NW Washington, D.C. 20460
PP.
178-184 .
Fremont, L. (2000) . Biological effects of resveratrol. Life Sci., 66: 663-673. Ganem Baez, F. A., Martin Gonzalez, O. (2000). Lectina concanavalina A: obtencibn y purificacidn. Universo
Diagnôstico. 1(1):1-41.
Ghosh, H. S., McBurney, M., Robbins, P. D. , McBurney,
R. (2010). SIRT1 negatively régulâtes the mammalian target of rapamycin. PLoS ONE 5 (2): e9199. Bibcode:2010PLoSO. 5.9199G. doi: 10.1371/journal.pone.0009199.PMC 2821410.PMID 20169165.
Gokaraju G. R., Gokaraju, R. R., Golakoti, V. K. R. R., Bhupathiraju, T., Sengupta, K., Alluri, K., Raju, V. K. (2016). Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome. Patent US 2016/9,241,964, Jan. 26, 2016.
Gualdrdn, R., Ldpez, S., Sanabria, A. (1997) . Estudio fitoquimico preliminar y letalidad sobre Artemia salina de plantas colombianas. Rev. Col. Quim. Farm. 26:15-19. Jiang, W. J. (2008). Sirtuins: novel targets for metabolic disease in drug development. Biochem. Biophys. Res. Commun. 373(3): 341-344.
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P., Auwerx, J. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-lalpha. Cell 127 (6) : 1109-1122. doi:10.1016/j.cell.2006.11.013. PMID 17112576.
Lodder, R. A., Cassis L. A. (2016). D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof. Patent US 2015/9,060,962, Jun. 23, 2015. Marti-Centelles, R., Falomir, E., Murga, J., Carda, M., Marco, J. A. (2015). Inhibitory effect of cytotoxic stilbenes related to resveratrol on the expression of the VEGF, hTERT and c-Myc genes. Eur J Med Chem. 103: 488-496. Michael, A. S., Thompson, C. G., Abramovitz, M. (1956). Artemia salina as test organims for a bioassay. Science. 123: 464.
Mosmann, T. (1983). Rapid calorimetric assay for cellular growth and survival: application to prolifération and cytotoxicity assays. J Immunol Methods. 65(1-2): 55-63. Olas, B., Wachowicz, B. (2005). Resveratrol, a phenolic antioxidant with effects on blood platelet functions. Platelets 16 (5): 251-260.
Prossnitz, E. R., Barton, M. (2014). Estrogen biology: New insights into GPER function and clinical opportunities. Molecular and Cellular Endocrinology. 389 (1-2): 71-83. doi: 10.1016/j.mce.2014.02.002. ISSN 03037207 .
Romero, T. (2016). Methods and materials for reducing multiple risk factors associated with the metabolic syndrome. Patent US 2016/9,278,104, Mar. 8, 2016. Vanhaecke, P., Persoone, G., Claus, C., Sorgeloos, P. (1981). Proposai for a short-term toxicity test with Artemia nauplii. Ecotoxicol Environ Saf. 5: 382-387.
Varfolomeev, S. D. , Gurevich, K. G. (2001) . Enzyme active sites: bioinformatics, architecture, and mechanisms of action. Russian Chemical Bulletin. 50 (10): 1709-1717. Wang, L., Waltenberger, B., Pferschy-Wenzig, E. M. , Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., Schuster,
D., Kopp, B., Bauer, R., Stuppner, H., Dirsch, V. M. , Atanasov, A. G. (2014). Naturel product agonists of peroxisome proliferator-activated receptor gamma (PPARy): a review. Biochem Pharmacol 92 (1) : 73-89. doi: 10.1016/j.bcp.2014.07.018. PMC 4212005. PMID 25083916. Wu, G. A. B., Meininger, C. J., Knabe, D. A., Baze, F. W. A., Rhoads, J. M. (2000) Arginine nutrition in development, health and disease. Current Opinion in Clinical Nutrition & Metabolic Care. 3 (1) : 59-66.
Claims (5)
1. A composition for use in the treatment or prévention of a metabolic syndrome, the composition comprising 3,0007,000 mg glycine, 300-5,000 mg arginine, 200-2,500 mg cysteine, and 100-2,500 mg resveratrol, wherein the composition is administered to a patient in need thereof.
2. The composition for use of claim 1, wherein the composition is an aqueous suspension, tablet, or polymer capsule.
-)O
3. The composition for use of claim 1, wherein the administering of the composition further reduces total cholestérol, low density lipoproteins, and triglycéride levels in blood of the patient.
4. The composition for use of claim 1, wherein the administering of the composition further reduces uric acid concentration in blood of the patient.
5. The composition for use administering of the composition volume in arteries of the patient.
of claim 1, wherein the further decreases plaque
administering of the composition further reduces high blood glucose concentration(s) of the patient.
8. The composition for bu-se of claim 1, wherein the administering of the composition further reduces progression severity of the metabolic syndrome of the patient.
9. The composition for use of claim 1, wherein the
5 administering of the composition further stimulâtes cell prolifération in organs of the patient damaged by metabolic syndrome.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/176,422 | 2016-06-08 | ||
MXMX/A/2017/007448 | 2017-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19128A true OA19128A (en) | 2020-01-31 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sheng et al. | Grape seed proanthocyanidin extract ameliorates dextran sulfate sodium-induced colitis through intestinal barrier improvement, oxidative stress reduction, and inflammatory cytokines and gut microbiota modulation | |
Tsuda | Recent progress in anti-obesity and anti-diabetes effect of berries | |
Shen et al. | Resveratrol pretreatment attenuates injury and promotes proliferation of neural stem cells following oxygen-glucose deprivation/reoxygenation by upregulating the expression of Nrf2, HO-1 and NQO1 in vitro | |
Kumar et al. | Cordyceps sinensis promotes exercise endurance capacity of rats by activating skeletal muscle metabolic regulators | |
Cui et al. | The effect of emodin on cytotoxicity, apoptosis and antioxidant capacity in the hepatic cells of grass carp (Ctenopharyngodon idellus) | |
US11419890B2 (en) | Compositions prepared from poultry and methods of their use | |
Chen et al. | Anti-aging effect of phlorizin on D-galactose–induced aging in mice through antioxidant and anti-inflammatory activity, prevention of apoptosis, and regulation of the gut microbiota | |
Lee | Regulation of Cytochrome c Oxidase by Natural Compounds Resveratrol,(–)-Epicatechin, and Betaine | |
US10039798B2 (en) | Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm | |
Bojarczuk et al. | Polyphenol Supplementation and Antioxidant Status in Athletes: A Narrative Review | |
He et al. | Oral L-theanine administration promotes fat browning and prevents obesity in mice fed high-fat diet associated with the modulation of gut microbiota | |
Munasinghe et al. | Cocoa improves age-associated health and extends lifespan in C. elegans | |
Shyur et al. | Extract of white sweet potato tuber against TNF-α-induced insulin resistance by activating the PI3K/Akt pathway in C2C12 myotubes | |
US10285963B2 (en) | Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases | |
Mirhashemi et al. | Effect of two herbal polyphenol compounds on human amylin amyloid formation and destabilization | |
Emami et al. | Effects of high intensity interval training and curcumin supplement on glutathione peroxidase (GPX) activity and malondialdehyde (MDA) concentration of the liver in STZ induced diabetic rats | |
OA19128A (en) | Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes. | |
EP3470060A2 (en) | Combination of bioenergy and nutra-epigenetic metabolic regulators, nutraceutical compounds in conventional and nanotechnology-based combinations, for reversing and preventing cellular senescence accelerated by chronic damage caused by diabetes and other complex chronic degenerative diseases | |
Khan et al. | Assessment of the role of anthocyanin standardized elderberry (Sambucus nigra) extract as an immune-stimulating nutraceutical of Nile tilapia, Oreochromis niloticus | |
Barari et al. | Effect of saffron extract and aerobic exercises on troponin T and heart-type fatty acid binding protein in type 2 diabetes patients | |
Heydarnia et al. | Effects of Eight Weeks of Combined Training with Antioxidant Vitamins E and C on Glutathione, Glutathione Peroxidase, and Superoxide Dismutase in the Heart Tissue of Streptozotocin-induced Diabetic Rats | |
Turska et al. | A Review of the Health Benefits of Food Enriched with Kynurenic Acid. Nutrients 2022, 14, 4182 | |
Li et al. | Prevention of obesity-induced nonalcoholic fatty liver disease using grape pomace extract. | |
Roxo et al. | The use of the nematode Caenorhabditis elegans to study antioxidant and longevity‑promoting plant secondary metabolites | |
Lie-Fen et al. | Extract of white sweet potato tuber against TNF-α-induced insulin resistance by activating the PI3K/Akt pathway in C2C12 myotubes |